rhinosinusitis%20-%20acute,%20bacterial
RHINOSINUSITIS - ACUTE, BACTERIAL
Acute bacterial rhinosinusitis is the mucosal inflammation of the nose and paransal sinuses caused by bacteria lasting >10 days for up to 4 weeks or symptoms worsening for 5-7 days within 10 days.
It is often preceded by a viral upper respiratory tract infection.
Signs and symptoms are nonspecific and typically difficult to differentiate from viral upper respiratory tract infection.
There is fever with nasal obstruction/congestion or anterior and/or posterior purulent drainage, with or without facial pressure/pain/fullness and reduction/loss of smell.
Streptococcus pneumoniae and unencapsulated strains of Haemophilus influenzae cause half of acute rhinosinusitis cases.

Symptomatic Therapy

  • Initial symptomatic management is the most cost-effective treatment strategy for many patients
  • Two-thirds of cases of acute rhinosinusitis resolve without antibiotic therapy
  • A course of 7-10 days of watchful waiting may be sufficient if the patient presents with assurance of follow-up & mild pain or temperature <38.3°C or 101°F
    • During the decision-making process, it is also important to consider patient’s age, general health, cardiopulmonary status & presence of comorbidities

Analgesics

  • Useful in controlling pain as >50% of patients with acute bacterial rhinosinusitis (ABRS) report facial pain
  • Antipyretics may be used to relieve fever

Cough Preparations

  • Routine prescription of mucolytics is not recommended
  • Guaifenesin is noted to be of some benefit but requires more studies

Corticosteroid Hormones

  • There is limited evidence to support use of oral corticosteroids in acute rhinosinusitis beyond pain relief
    • Intranasal corticosteroid may be used as an adjunct to empiric antibiotic therapy in patients with allergic rhinitis history
  • In a randomized, double-blind, double-dummy study of patients with nonsevere ABRS, twice-daily use of Mometasone nasal spray has been shown to significantly improve the symptom score compared to patients who received Amoxicillin & placebo
  • There is some evidence to the benefit of nasal Budesonide used with Erythromycin in ABRS, but only toward symptom reduction
  • There are minimal long-term effects to short-term use of nasal corticosteroids

Decongestants (Oral/Intranasal)

  • Increase the ostial diameter by reducing turbinate swelling and mucosal edema; may promote sinus drainage
  • Oral and intranasal decongestants may be beneficial in ABRS
  • Overuse of intranasal decongestants or use for periods longer than 3-7 days is not recommended due to the risk of rebound vasodilation
  • Based on clinical experience, intranasal decongestants are more effective and penetrate rapidly than oral decongestants

Antihistamines

  • Use of antihistamines is not recommended; may only be used as an adjunct to antibiotic therapy in patients with concomitant allergic rhinitis

Saline

  • The use of nasal saline irrigation, alone or as adjunct, has been shown to reduce the symptoms and medication use
  • Facilitates removal of infective agents, mucus and inflammatory mediators
  • Decreases crusting of the nasal cavity
  • Increases mucociliary clearance
  • There is no difference in symptoms score when comparing isotonic with hypertonic saline, although hypertonic solutions have been shown to improve mucociliary clearance

Otolaryngologist Referral

Consider expert referral if any of the following occurs:

  • If no improvement from 1st- or 2nd-line agents especially in severely ill or immunocompromised patients with:
    • Uncontrolled diabetes
    • End-stage renal failure
  • Recurrent bacterial rhinosinusitis (≥4 episodes/year)
  • Granulomatous disease or fungal sinusitis
  • Development of complications
  • Chronic rhinosinusitis with frequent acute bacterial rhinosinusitis (ABRS) exacerbations
  • Unusual opportunistic or resistant organisms
  • Anatomical anomalies that causes obstruction
  • Failure to respond to extended antibiotic courses
  • Presence of comorbidities
  • Hospital-acquired infection
  • Suspected malignancy

Emergency specialist referral is needed if any of the following is present:

  • Periorbital cellulitis or preseptal edema
  • Displacement of orbital globe
  • Double vision
  • Eye pain/ophthalmoplegia
  • Reduced visual acuity
  • Severe unilateral or bilateral frontal headache
  • Frontal sinus swelling
  • Meningeal or focal neurologic signs eg high fever, signs of meningeal irritation, altered mental status
  • Signs of cavernous sinus thrombosis (eg bilateral lid drop, ophthalmic nerve neuralgia, retro-ocular headache, complete ophthalmoplegia, papilledema, prostration)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, Yesterday
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 4 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
15 Jun 2018
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
Jairia Dela Cruz, Yesterday
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.